Glimepirid Al

Glimepirid Al is a prescription oral medication that contains the active ingredient glimepiride. It is supplied as tablets (strength not specified) and is marketed in the European Union. Glimepiride belongs to the sulfonylurea class of antidiabetic agents and works by stimulating insulin release from pancreatic beta cells to help control blood glucose in adults with type 2 diabetes. The product is intended for use under medical supervision.

Glimepirid Al is indicated for the management of hyperglycemia in patients with type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient.

- As monotherapy in adults with type 2 diabetes inadequately controlled by lifestyle measures. - In combination with metformin when additional glucose lowering is required. - As part of a fixed‑dose combination regimen with other oral antidiabetic agents. - To improve glycemic control in patients who have a preserved pancreatic beta‑cell function. - For use in patients who require a once‑daily oral sulfonylurea.

Glimepirid Al may cause a range of adverse effects, most of which are dose‑related and reversible after discontinuation. These events are reported in clinical studies and post‑marketing surveillance.

Common: - Mild hypoglycemia, especially when meals are skipped or delayed. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient visual disturbances.

Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic reactions such as rash, pruritus, or angio‑edema. - Hematologic abnormalities including leukopenia or thrombocytopenia. - Hepatic dysfunction presenting as elevated transaminases. - Severe hypoglycemia leading to loss of consciousness.

Before prescribing Glimepirid Al, clinicians should evaluate patient history and monitor specific conditions to minimize risk.

- Assess renal and hepatic function; dose adjustment may be required in impairment. - Verify that the patient has adequate pancreatic beta‑cell reserve. - Caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use in patients with known sulfonylurea hypersensitivity. - Counsel patients on recognizing and managing hypoglycemic episodes. - Review concomitant use of alcohol, which can potentiate hypoglycemia.

Glimepirid Al can interact with several medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin, which may cause severe hypoglycemia. - Strong CYP2C9 inhibitors such as fluconazole or amiodarone, which can raise glimepiride plasma levels. - Discontinuation of beta‑blockers without medical guidance, as they may mask hypoglycemia symptoms. - High‑dose corticosteroids, which may counteract the drug’s efficacy.

Use with caution: - Loop or thiazide diuretics, which can affect blood glucose control. - Antifungal agents like itraconazole that moderately inhibit CYP2C9. - NSAIDs and aspirin, which may enhance the hypoglycemic effect. - Thyroid hormones, which may alter glucose metabolism.